A director at AlzChem Group AG sold 250,000 shares at 116.750EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
The previous high has been passed, the bullish trend is confirmed. The next target is at CHF 289.50. The invalidation level is below CHF 270.00.Arguments :- The major resistance has been breached.- Prices made a new all-time-high, this confirms the strength of the trend.-...
Le précédent sommet vient d'être franchi, ceci confirme la tendance haussière. Le prochain objectif est à 289,50 CHF. Le niveau d'invalidation est sous 270,00 CHF.Arguments :- La résistance majeure est dépassée.- Les cours font un nouveau plus haut historique, ce qui témoigne de...
The previous high has been passed, the bullish trend is confirmed. The next target is at CHF 289.50. The invalidation level is below CHF 262.00.Arguments :- The major resistance has been breached.- Prices made a new all-time-high, this confirms the strength of the trend.-...
Le précédent sommet vient d'être franchi, ceci confirme la tendance haussière. Le prochain objectif est à 289,50 CHF. Le niveau d'invalidation est sous 262,00 CHF.Arguments :- La résistance majeure est dépassée.- Les cours font un nouveau plus haut historique, ce qui témoigne de...
Les sommets et les creux ne sont pas particulièrement inclinés, la tendance est neutre. Les cours consolident.Arguments :- Le support est proche.- La moyenne mobile, sans tendance, confirme notre avis.- Les prix évoluent dans un rectangle.
The general evaluation of ACTELION LTD. (CH), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date August 15, 2017, the closing price was CHF 274.00...
The trend is still bullish, the invalidation level is below CHF 247.34. The target is at CHF 304.19.Arguments :- Prices made a new all-time-high, this confirms the strength of the trend.- The rising moving average confirms our opinion.- A trend is momentarily interrupted by...
La tendance est toujours haussière, son niveau d'invalidation est sous 247,34 CHF. L'objectif est à 304,19 CHF.Arguments :- Les cours font un nouveau plus haut historique, ce qui témoigne de la force de la tendance.- La moyenne mobile, haussière, confirme notre avis.- Un...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.